Congratulations to Trevor Martin, CEO of Mammoth Biosciences, who was featured on Forbes 2019 Healthcare 30 Under 30. Trevor is a 29-year-old Stanford biology PhD who wanted to create diagnostic tests, and not drugs. To do that, he happened upon one of the hottest technologies in biotech: an enzyme called CRISPR. Rather than using it as a method for genetic editing, new research from the UC Berkeley lab of CRISPR co-discoverer Jennifer Doudna showed it was possible to use it as not only a pair of scissors, but as a genetic search engine. They are developing this technology to detect viral diseases like Zika.
In just ten months of operating lab space at MBC BioLabs San Francisco, the team has raised a $23 million Series A from Mayfield, 8VC, and Mission Bay Capital.
Full Press Release